Pharmacokinetics of aluminum 3-hydroxypyridin-4-one complexes: implications for aluminum redistribution subsequent to chelation therapy.

[1]  K. Brouwer,et al.  Toxicokinetics of Intravenous Methanol in the Female Rat , 1993 .

[2]  R. Hider,et al.  Pharmacokinetics of representative 3-hydroxypyridin-4-ones in rabbits: CP20 and CP94. , 1993, Drug metabolism and disposition: the biological fate of chemicals.

[3]  S. Sandroni,et al.  Aluminium intoxication in undialysed adults with chronic renal failure. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[4]  C. Orvig,et al.  1-n-Propyl- and 1-n-butyl-3-hydroxy-2-methyl-4-pyridinone complexes of group 13 (IIIA) metal ions , 1991 .

[5]  E. G. Jackson,et al.  Evaluation of potential aluminum chelators in vitro by aluminum solubilization ability, aluminum mobilization from transferrin and the octanol/aqueous distribution of the chelators and their complexes with aluminum. , 1991, The Journal of pharmacology and experimental therapeutics.

[6]  U. Ungerstedt,et al.  Aluminum distribution into brain and liver of rats and rabbits following intravenous aluminum lactate or citrate: a microdialysis study. , 1991, Toxicology and applied pharmacology.

[7]  E. Huehns,et al.  The Development of Hydroxypyridin‐4‐ones as Orally Active Iron Chelators , 1990, Annals of the New York Academy of Sciences.

[8]  R. Puniyani,et al.  Oral iron chelation with L1 , 1990, The Lancet.

[9]  C. Orvig,et al.  Comparison of ligands of differing denticity and basicity for the in vivo chelation of aluminium and gallium , 1990 .

[10]  C. Orvig,et al.  Aluminum and gallium complexes of 1-ethyl-3-hydroxy-2-methyl-4-pyridinone: a new exoclathrate matrix , 1989 .

[11]  C. Orvig,et al.  The complexation of aluminum with N-substituted 3-hydroxy-4-pyridinones , 1989 .

[12]  R. Hider,et al.  Investigation of the anti-inflammatory properties of hydroxypyridinones. , 1989, Annals of the rheumatic diseases.

[13]  P. Harrison,et al.  Release of iron from ferritin molecules and their iron-cores by 3-hydroxypyridinone chelators in vitro. , 1989, Journal of Inorganic Biochemistry.

[14]  R. Yokel.  Aluminum and Alzheimer's Disease: Should We Worry? , 1988 .

[15]  P. McNamara,et al.  Influence of renal impairment, chemical form, and serum protein binding on intravenous and oral aluminum kinetics in the rabbit. , 1988, Toxicology and applied pharmacology.

[16]  C. Orvig,et al.  Aluminum and gallium compounds of 3-hydroxy-4-pyridinones: synthesis, characterization, and crystallography of biologically active complexes with unusual hydrogen bonding , 1988 .

[17]  G. Kontoghiorghes,et al.  Simple synthesis of the potent iron chelators 1-alkyl-3-hydroxy-2-methylpyrid-4-ones , 1987 .

[18]  E. Chew,et al.  Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. , 1986, The New England journal of medicine.

[19]  M. Tichy̌,et al.  QSAR Analysis and Data Extrapolation among Mammals in a Series of Aliphatic Alcohols , 1985 .

[20]  J. Lunec,et al.  Cerebral and ocular toxicity induced by desferrioxamine. , 1985, The Quarterly journal of medicine.

[21]  S. Colan,et al.  Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. , 1985, The New England journal of medicine.

[22]  V. Parsons,et al.  Aluminium-induced anaemia in haemodialysis patients. , 1985, Nephron.

[23]  A. Sedman,et al.  Encephalopathy in childhood secondary to aluminum toxicity. , 1984, The Journal of pediatrics.

[24]  G. Arden,et al.  OCULAR TOXICITY OF HIGH-DOSE INTRAVENOUS DESFERRIOXAMINE , 1983, The Lancet.

[25]  S. Ott,et al.  The prevalence of bone aluminum deposition in renal osteodystrophy and its relation to the response to calcitriol therapy. , 1982, The New England journal of medicine.

[26]  S. Sideman,et al.  The dialysis dementia syndrome and aluminum intoxication. , 1982, Nephron.

[27]  O. Oster.  The aluminium content of human serum determined by atomic absorption spectroscopy with a graphite furnace. , 1981, Clinica chimica acta; international journal of clinical chemistry.

[28]  A. Alfrey,et al.  Metabolism and toxicity of aluminum in renal failure. , 1980, The American journal of clinical nutrition.

[29]  W. D. Kaehny,et al.  The dialysis encephalopathy syndrome. Possible aluminum intoxication. , 1976, The New England journal of medicine.

[30]  O. Röe.  THE METABOLISM AND TOXICITY OF METHANOL , 1955 .